| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.16 | 0.001 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.091 | 0.007 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.008 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.01 |